Longboard Pharmaceuticals, Inc. (LBPH)
NASDAQ: LBPH · Real-Time Price · USD
59.76
+0.01 (0.01%)
Nov 19, 2024, 1:22 PM EST - Market open

Company Description

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases.

The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.

It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020.

Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals logo
Country United States
Founded 2020
IPO Date Mar 12, 2021
Industry Biotechnology
Sector Healthcare
Employees 50
CEO Kevin Lind

Contact Details

Address:
4275 Executive Square, Suite 950
La Jolla, California 92037
United States
Phone 858 789 9283
Website longboardpharma.com

Stock Details

Ticker Symbol LBPH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001832168
CUSIP Number 54300N103
ISIN Number US54300N1037
Employer ID 84-5009619
SIC Code 2834

Key Executives

Name Position
Kevin R. Lind President, Chief Executive Officer, Secretary and Director
Brandi L. Roberts CPA, M.B.A. Executive Vice President and Chief Financial Officer
Dr. Randall E. Kaye M.D. Executive Vice President and Chief Medical Officer
Chadwick J. Orevillo MPH Executive Vice President and Head of Operations
Steven W. Spector J.D. Executive Vice President, Head of Business Development and General Counsel

Latest SEC Filings

Date Type Title
Nov 15, 2024 SC TO-T/A Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Nov 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals